Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
CollPlant Biotechnologies (NAS:CLGN) Forward PE Ratio Explanation
The Forward PE Ratio of a company is often used to compare current earnings to estimated future earnings, as well as gaining a clearer picture of what earnings will look like without charges and other accounting adjustments. If earnings are expected to grow in the future, the Forward PE Ratio will be lower than the current PE Ratio. This measure is also used to compare one company to another with a forward-looking focus.
Trailing PE Ratio relies on what is already done. It uses the current share price and divides by the total EPS (Basic) over the past 12 months. PE Ratio can be affected by Non Operating Income such as the sale of part of businesses. This may increase for the current year or quarter dramatically. But it cannot be repeated over and over. Therefore PE Ratio without NRI is a more accurate indication of valuation than PE Ratio .
CollPlant Biotechnologies Forward PE Ratio Related Terms
CollPlant Biotechnologies Forward PE Ratio Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
CollPlant Biotechnologies Forward PE Ratio Chart
CollPlant Biotechnologies Annual Data
Trend
2021-12
Forward PE Ratio
9.20
CollPlant Biotechnologies Quarterly Data
2021-06
2021-09
2021-12
2022-03
2022-06
Forward PE Ratio
28.74
8.70
9.20
7.43
4.83
CLGN vs CPMV, TCRT, DRMA: Forward PE Ratio Comparison
For the Biotechnology subindustry, CollPlant Biotechnologies's Forward PE Ratio, along with its competitors' market caps and Forward PE Ratio data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
CollPlant Biotechnologies Forward PE Ratio vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, CollPlant Biotechnologies's Forward PE Ratio distribution charts can be found below:
* The bar in red indicates where CollPlant Biotechnologies's Forward PE Ratio falls into.
CollPlant Biotechnologies Forward PE Ratio Calculation
It's a measure of the price-to-earnings ratio (PE Ratio) using forecasted earnings for the calculation. While the earnings used are just an estimate and are not as reliable as current earnings data, there is still benefit in estimated P/E analysis. The forecasted earnings used in the formula can either be for the next 12 months or for the next full-year fiscal period.
CollPlant Biotechnologies (CLGN) has a Forward PE Ratio of 38.24 as of Jul. 25, 2026. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on CollPlant Biotechnologies and its competitors. According to the industry distribution chart, CollPlant Biotechnologies ranks #234 out of 355 companies in the Biotechnology industry, placing it in the top 65.9%.
Is CollPlant Biotechnologies' Forward PE Ratio too high?
CollPlant Biotechnologies' current Forward PE Ratio is 38.24. The Biotechnology industry median Forward PE Ratio is 21.68. CollPlant Biotechnologies' value of 38.24 is 76.4% above this industry median. Based on the distribution chart, CollPlant Biotechnologies ranks #234 out of 355 companies in the Biotechnology industry, which is below the industry midpoint. Overall, CollPlant Biotechnologies has a GF Score™ of 35/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does CollPlant Biotechnologies' Forward PE Ratio compare to CPMV and TCRT?
According to the Biotechnology industry distribution chart, CollPlant Biotechnologies ranks #234 out of 355 companies for Forward PE Ratio. This places CollPlant Biotechnologies in the lower half of its industry. The industry median Forward PE Ratio is 21.68. CollPlant Biotechnologies' value of 38.24 is 76.4% above this benchmark. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Forward PE Ratio for a Biotechnology company?
The median Forward PE Ratio among Biotechnology companies is 21.68, based on 355 companies in the industry. Companies in the top quartile (top 25%) have a Forward PE Ratio significantly above this median, while those in the bottom quartile fall well below. However, Forward PE Ratio should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. CollPlant Biotechnologies's current Forward PE Ratio of 38.24 is 76.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Forward PE Ratio mean?
A high Forward PE Ratio can signal that a stock is expensive relative to its fundamentals. Forward P/E ratio is the share price dividend by the expected per-share earnings in the next 12 months. View historical data on CollPlant Biotechnologies and its competitors. For the Biotechnology industry, the median Forward PE Ratio is 21.68 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. CollPlant Biotechnologies's current Forward PE Ratio is 38.24. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CollPlant Biotechnologies stock overvalued right now?
Based on GuruFocus' analysis, CollPlant Biotechnologies (CLGN) is currently considered Fairly Valued. The stock's GF Value™ is $0.29, compared to a current price of $0.31 — trading 8.6% above its estimated fair value. The current Forward PE Ratio is 38.24 and 76.4% above the Biotechnology industry median of 21.68. CollPlant Biotechnologies' overall GF Score™ is 35/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Forward PE Ratio calculated?
Forward PE Ratio is calculated from a company's financial statements. For CollPlant Biotechnologies (CLGN), the current Forward PE Ratio is 38.24 as of Jul. 25, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is CollPlant Biotechnologies (CLGN) Overvalued in 2026?
Based on GuruFocus' analysis, CollPlant Biotechnologies stock appears to be overvalued.
The current stock price of $0.31 is trading 8.6% above its estimated GF Value™ of $0.29.
GuruFocus considers CollPlant Biotechnologies to be Fairly Valued.
Key valuation signals for CLGN:
Forward PE Ratio: 38.24
GF Value™: $0.29 vs. price of $0.31 (8.6% above fair value)
Industry Position: 76.4% above the Biotechnology median (#234 of 355)
No single metric tells the full story. See the CLGN stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
CollPlant Biotechnologies Ltd is a regenerative and aesthetic medicine company focused on 3D bioprinting of tissues and organs and medical aesthetics. Its products are based on its rhCollagen (recombinant human collagen) produced with CollPlant's proprietary plant based genetic engineering technology. These products address indications for the diverse fields of tissue repair, aesthetics, and organ manufacturing. The revenues include income from business collaborators and sales of the BioInk product for the development of 3D bioprinting of organs and tissues, sales of rhCollagen for the medical aesthetics market, and sales in Europe of the products for tendinopathy and wound healing. The company operates in United States, which derives majority revenue, Canada, Europe and Other, and Israel.
35GF Score
Get the complete analysis for CLGN
Forward PE Ratio is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
CLGN has been successfully added to your 
